# Molecular mechanisms involved in the protective role of olive oil in the development of atherosclerotic processes

| Submission date<br>16/06/2009       | <b>Recruitment status</b><br>No longer recruiting | Prospectively registered        |  |  |
|-------------------------------------|---|---------------------------------|--|--|
|                                     |   | [_] Protocol                    |  |  |
| <b>Registration date</b> 28/07/2009 | <b>Overall study status</b><br>Completed          | [] Statistical analysis plan    |  |  |
|                                     |   | [X] Results                     |  |  |
| Last Edited<br>17/08/2010           | <b>Condition category</b><br>Circulatory System   | [_] Individual participant data |  |  |

## Plain English summary of protocol

Not provided at time of registration

# **Contact information**

**Type(s)** Scientific

**Contact name** Ms Anna Blasco

## **Contact details**

PRBB IMIM-Hospital del Mar URLEC Dr. Aiguader, 88 Barcelona Spain 08003 ablasco@imim.es

# Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

## Scientific Title

Molecular mechanisms involved in the protective role of olive oil in the development of atherosclerotic processes: a parallel randomised controlled double-blind clinical trial with three arms of dietary intervention

#### **Study objectives**

A traditional Mediterranean diet will modulate the expression of protective genes related with atherosclerosis processes. Virgin olive oil rich in phenolic compounds will provide further benefits.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

```
The local medical ethics committee (Comitè Ètic d'Investigació Clínica de l'Institut Municipal d'Assistència Sanitària [CEIC-IMAS]) approved on the 13th September 2004 (ref: 2004/1827/I)
```

#### Study design

Parallel randomised controlled double-blind clinical trial

**Primary study design** Interventional

Secondary study design Randomised controlled trial

# Study setting(s)

GP practice

#### Study type(s) Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Cardiovascular risk

#### Interventions

Volunteers were grouped randomly into three groups (n = 30 each one) to receive during 3 months the following treatments:

- 1. Traditional Mediterranean diet with virgin olive oil (TMD+VOO)
- 2. Traditional Mediterranean diet with washed virgin olive oil (TMD+WOO)
- 3. Habitual diet

For obtaining the washed virgin olive oil, the virgin olive used for the Group 1 treatment was washed by a procedure developed in the Instituto de la Grasa, Sevilla, Spain. This washed virgin olive oil maintained the same characteristics as group 1's virgin olive oil with the exception of the phenolic content which was not present. Olive oils were provided to the subjects of both groups 1 and 2 in sufficient amount for the entire family (15 L/per volunteer) during the intervention period of for cooking and raw purposes. Volunteers were assessed by the nutritionist to maintain their habitual lifestyle (i.e, physical activity, etc). Volunteers of groups 1 and 2 received intensive nutritional advice by trained nutritionists concerning the traditional Mediterranean diet pattern. At the end of the intervention, volunteers compliance was evaluated by values of tyrosol and hydroxytyrosol, the major virgin olive oil phenolic compounds in their first morning spot urine samples.

#### Intervention Type

Drug

**Phase** Not Applicable

#### Drug/device/biological/vaccine name(s)

Olive oil (with/without phenolic content)

#### Primary outcome measure

Gene expression changes related to cardiovascular risk, measured at baseline and after 3 months of intervention. Blood samples were collected from 8.00 to 10.00 a.m. at fasting state. Spot morning urine samples were collected.

#### Secondary outcome measures

Oxidative stress and Inflammation, measured at baseline and after 3 months of intervention. Blood samples were collected from 8.00 to 10.00 a.m. at fasting state. Spot morning urine samples were collected.

**Overall study start date** 20/10/2007

Completion date 20/10/2008

# Eligibility

**Key inclusion criteria** Healthy volunteers aged 20 - 50 years old, either sex

Participant type(s) Healthy volunteer

**Age group** Adult

**Sex** Both

## Target number of participants

90 volunteers (45 men and 45 women)

#### Key exclusion criteria

1. Intake of antioxidant supplements

2. Intake of acetosalicylic acid

3. Intake of any other drug with established antioxidative properties

4. Athletes with high physical activity (greater than 3000 kcal per week in leisure-time physical activity)

5. Obesity (body mass index [BMI] greater than 30 kg/m^2)

6. Hypercholestrolaemia greater than 8.0 mmol per litre or dyslipidaemia therapy indication 7. Diabetes

8. Hypertension (systolic blood pressure [SBP] greater than 140 mmHg, diastolic blood pressure [DBP] greater than 90 mmHg)

9. Multiple allergies

10. Coeliac or other intestinal diseases

11. Any condition that limits the mobility of the subject making study visits impossible

12. Life-threatening illnesses such as cancer or a severe disease with a less than 3-year expectancy

13. Other diseases or conditions that could worsen adherence to the measurements or treatments

14. Vegetarians and people following special diets

15. Alcoholism or other drug addiction

Date of first enrolment 20/10/2007

Date of final enrolment

20/10/2008

## Locations

Countries of recruitment Spain

**Study participating centre PRBB** Barcelona Spain 08003

# Sponsor information

## Sponsor details

C/Prim, 12 Madrid Spain 28004 info@pco.es

#### Sponsor type

Industry

Website http://www.pco.es/

## Funder(s)

**Funder type** Hospital/treatment centre

#### **Funder Name**

The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain) - Fondo de Investigacion Sanitaria (FIS-FEDER)

## **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Not provided at time of registration

#### Study outputs

| Output type     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-----------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/07/2010   |            | Yes            | No              |